Why the study?
Does single-lead VDD pacing reduce treatment costs compared to DDD pacing in patients with atrioventricular block?
Does single-lead VDD pacing reduce treatment costs compared to DDD pacing in patients with atrioventricular block?
Single-lead VDD pacemakers significantly reduce implantation and follow-up costs compared to DDD systems without compromising therapeutic efficacy in patients with atrioventricular block.
No takes yet. Share an insight, caveat, or question.
VDD-associated cost reductions should not yet change practice; leaves open whether single-lead pacing warrants randomized confirmation in AV block.
Uwe Wiegand (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: